These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28892923)

  • 1. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.
    Indumathi C; Anusha N; Vinod KV; Santhosh S; Dkhar SA
    J Clin Diagn Res; 2017 Jul; 11(7):FC01-FC05. PubMed ID: 28892923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series.
    Cham S; Koslik HJ; Golomb BA
    Drug Saf Case Rep; 2016 Dec; 3(1):1. PubMed ID: 27747681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of Adverse Drug Reactions Reported with Cardiovascular Drugs in a Tertiary Care Teaching Hospital.
    Palaniappan M; Selvarajan S; George M; Subramaniyan G; Dkhar SA; Pillai AA; Jayaraman B; Chandrasekaran A
    J Clin Diagn Res; 2015 Nov; 9(11):FC01-4. PubMed ID: 26675485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians' Experiences as Patients with Statin Side Effects: A Case Series.
    Koslik HJ; Meskimen AH; Golomb BA
    Drug Saf Case Rep; 2017 Dec; 4(1):3. PubMed ID: 28217821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients.
    Kumar M; Rehan HS; Puri R; Yadav M; Gupta LK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S64-S67. PubMed ID: 30595323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis.
    Du Y; Wang S; Chen Z; Sun S; Zhao Z; Li X
    Curr Pharm Des; 2018; 24(34):4044-4050. PubMed ID: 30569848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Drug Reactions Attributed to Fondaparinux and Unfractionated Heparin in Cardiovascular Care Unit: An Observational Prospective Pilot Study in a Tertiary Care Hospital.
    Sharma S; Swamy S; Bhambhani A; Nadig P
    J Pharm Bioallied Sci; 2018; 10(2):90-95. PubMed ID: 29962798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
    Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
    J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Newman CB; Szarek M; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Demicco DA; Auster S; Fuller JH;
    Diab Vasc Dis Res; 2008 Sep; 5(3):177-83. PubMed ID: 18777490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus.
    Castaño G; Fernández L; Mas R; Illnait J; Mesa M; Fernández JC
    Clin Drug Investig; 2003; 23(10):639-50. PubMed ID: 17535079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Outcomes of Atorvastatin 80 mg Versus Atorvastatin 40 mg in a Veteran Population.
    Jacobs D; Wassell K; Guidry TJ; Sullivan J
    Ann Pharmacother; 2020 Feb; 54(2):151-156. PubMed ID: 31544472
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
    Stein B; Ward T; Hale G; Lyver E
    Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
    [No Abstract]   [Full Text] [Related]  

  • 15. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital.
    Mateti UV; Nekkanti H; Vilakkathala R; Rajakannan T; Mallayasamy S; Ramachandran P
    N Am J Med Sci; 2012 Apr; 4(4):185-9. PubMed ID: 22536562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy.
    Sharma JB; Krishnamurthy MN; Awase A; Joshi A; Patil V; Noronha V; Prabhash K; Gota V
    Ther Adv Drug Saf; 2021; 12():2042098621991280. PubMed ID: 33628419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
    März W; Wollschläger H; Klein G; Neiss A; Wehling M
    Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.